Press release
Anaplastic Thyroid Cancer Pipeline 2025: Innovative Clinical Developments by 8+ Global Leaders - DelveInsight | Featuring companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceu
Anaplastic Thyroid Cancer Pipeline 2025
With anaplastic thyroid cancer increasingly prevalent worldwide and contributing to comorbidities like diabetes, cardiovascular disease, and other cancers, there is a rising demand for safer and more effective treatments. According to DelveInsight, the anaplastic thyroid cancer pipeline involves 8+ pharmaceutical and biotech companies developing 8+ therapeutic candidates. These therapies are at various stages of clinical and preclinical development, highlighting substantial innovation and dedication to tackling this critical public health challenge.
DelveInsight's report, "Anaplastic Thyroid Cancer Pipeline Insight 2025," offers a comprehensive and strategic review of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving anaplastic thyroid cancer therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Anaplastic Thyroid Cancer Drug Development @ https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
*
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
*
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
*
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
*
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
*
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
*
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER Trademark program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
*
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
*
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT Trademark study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
*
DelveInsight's Anaplastic Thyroid Cancer pipeline report highlights a dynamic landscape with 8+ active companies developing 8+ therapeutic candidates for the treatment of anaplastic thyroid cancer.
*
In August 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AIC100, an investigational CAR T-cell therapy targeting ICAM-1, for the treatment of recurrent ATC.
*
Leading companies in the anaplastic thyroid cancer space-including Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others-are actively developing new therapies to enhance treatment options.
*
Promising pipeline candidates in development include Sapanisertib, HLX208, and several others.
Anaplastic Thyroid Cancer Overview:
Anaplastic thyroid cancer (ATC) is a rare and highly aggressive type of thyroid cancer. The thyroid gland, located at the front of the neck just below the Adam's apple, produces essential hormones for the body. Unlike other thyroid cancers, ATC spreads quickly to other parts of the body. It primarily affects people over the age of 60 and is also referred to as anaplastic thyroid carcinoma.
Although uncommon, ATC accounts for only 1% to 2% of all thyroid cancer cases, with approximately one to two diagnoses per million people annually in the United States. The disease often starts as a lump in the neck, and as the tumor enlarges, it can press on the vocal cords, causing hoarseness, or obstruct the windpipe, making breathing difficult. In some instances, small tumors may go unnoticed for a period of time.
Download the Anaplastic Thyroid Cancer sample report to know in detail about the Anaplastic Thyroid Cancer treatment market [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Anaplastic Thyroid Cancer Pipeline Analysis
The Anaplastic Thyroid Cancer pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Anaplastic Thyroid Cancer Market.
*
Categorizes Anaplastic Thyroid Cancer therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Anaplastic Thyroid Cancer drugs under development based on:
*
Stage of development
*
Anaplastic Thyroid Cancer Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Anaplastic Thyroid Cancer Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Anaplastic Thyroid Cancer Licensing agreements
*
Funding and investment activities supporting future Anaplastic Thyroid Cancer market advancement.
Unlock key insights into emerging Anaplastic Thyroid Cancer therapies and market strategies here:https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Anaplastic Thyroid Cancer Emerging Drugs
Sapanisertib - Takeda
Sapanisertib is a dual TORC1/2 inhibitor designed to target a critical survival pathway in tumor cells harboring KEAP1/NRF2 mutations, which are frequently observed in many patients with various solid tumors. The drug has shown promising results as a monotherapy in patients with relapsed or treatment-resistant NRF2-mutated squamous non-small cell lung cancer (NSCLC). In preclinical studies, sapanisertib exhibited distinct anti-tumor activity compared to TORC1-specific rapalogs in NRF2-mutated squamous NSCLC models.
HLX208 - Shanghai Henlius Biotech
HLX208 is a small-molecule inhibitor designed to target the BRAF V600E mutation, with potential applications across multiple solid tumors. The therapy may be combined with Henlius's proprietary EGFR- or PD-1-targeting antibodies, supporting the development of a strong, innovative, and differentiated oncology portfolio for diverse cancer indications.
Anaplastic Thyroid Cancer Pipeline Therapeutic Assessment
Anaplastic Thyroid Cancer Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Anaplastic Thyroid Cancer By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Anaplastic Thyroid Cancer Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Anaplastic Thyroid Cancer Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Anaplastic Thyroid Cancer therapies and key Anaplastic Thyroid Cancer companies [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Anaplastic Thyroid Cancer Current Treatment Patterns
8. Anaplastic Thyroid Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
8. Anaplastic Thyroid Cancer Late-Stage Products (Phase-III)
7. Anaplastic Thyroid Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
8. Inactive Products
11. Dormant Products
12. Anaplastic Thyroid Cancer Discontinued Products
13. Anaplastic Thyroid Cancer Product Profiles
18. Anaplastic Thyroid Cancer Key Companies
15. Anaplastic Thyroid Cancer Key Products
18. Dormant and Discontinued Products
17. Anaplastic Thyroid Cancer Unmet Needs
18. Anaplastic Thyroid Cancer Future Perspectives
19. Anaplastic Thyroid Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Anaplastic Thyroid Cancer pipeline reports offerings: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anaplastic-thyroid-cancer-pipeline-2025-innovative-clinical-developments-by-8-global-leaders-delveinsight-featuring-companies-such-as-takeda-shanghai-henlius-biotech-taizhou-hanzhong-pharmaceu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Thyroid Cancer Pipeline 2025: Innovative Clinical Developments by 8+ Global Leaders - DelveInsight | Featuring companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceu here
News-ID: 4204528 • Views: …
More Releases from ABNewswire
Bardet-Biedl Syndrome Pipeline 2025: Pioneering Clinical Developments by 8+ Glob …
DelveInsight's, "Bardet-Biedl Syndrome - Pipeline Insight, 2025," report provides comprehensive insights about 1+ companies and 1+ pipeline drugs in Bardet-Biedl Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Bardet-Biedl Syndrome (BBS) increasingly impacting populations worldwide and contributing…
Brain Metastases Pipeline 2025: Pioneering Clinical Advancements by 40+ Global L …
Brain Metastases companies are Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, and others.
With brain metastases increasingly prevalent worldwide and contributing to comorbid conditions such as diabetes, cardiovascular…
Cabinets 4 Less Scottsdale Showroom Offers Affordable Cabinetry Solutions
Cabinets 4 Less Scottsdale, a premier cabinet store located at 8445 E. McDonald Dr. in Scottsdale, AZ, is expanding its showroom to offer homeowners, contractors, and designers affordable, high-quality cabinetry. With a wide selection of styles and finishes, personalized consultations, and reliable service, the store provides cost-effective solutions for remodeling and construction projects in Scottsdale's growing housing market.
SCOTTSDALE, AZ - September 30, 2025 - Cabinets 4 Less Scottsdale [https://cabinets4lessscottsdale.com], a…
Hypercholesterolemia Pipeline 2025: Innovative Clinical Advancements by 25+ Glob …
DelveInsight's, "Hypercholesterolemia- Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hypercholesterolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With hypercholesterolemia reaching global epidemic proportions and contributing to comorbid conditions such as…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Large Cell Lymphoma Drugs Market: An In-Depth Analysis
The global Anaplastic Large Cell Lymphoma Drugs market was valued approximately USD 10.5 billion in 2022 and is projected to reach around USD 17.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period.
Anaplastic Large Cell Lymphoma Drugs Market Overview
Anaplastic Large Cell Lymphoma is a rare type of non-Hodgkin lymphoma characterized by the proliferation of large lymphoid cells. The market for ALCL…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
